GANX Gain Therapeutics, Inc.
Gain Therapeutics, Inc. (GANX) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.13 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +19.1% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is positioned at the confluence of technology and healthcare and focused on redefining drug discovery with its SEE-Tx™ target identification platform.
Sector
Healthcare
Industry
Biotechnology